NEOS Investment Management LLC flexed its biotech muscles by upping its stake in Regeneron Pharmaceuticals by a hearty 30.6% in Q4. The firm now owns 17,650 shares worth a tidy $12.57 million, proving ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

Adam Schleifer, a longtime financial fraud prosecutor, was dismissed from the U.S. Attorney's office in L.A. on Friday. He ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Regeneron Pharmaceuticals just belly-flopped into a fresh 12-month low, trading as low as $640.28—Wall Street winced. Analyst ...